Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1126/science.207.4427.167 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel high-stopping power scintillators for medical applications.
Proc SPIE Int Soc Opt Eng
February 2024
Radiation Monitoring Devices, Inc., 44 Hunt St., Watertown, MA, USA 02472- 4624.
Development of new scintillator materials is a continuous effort, which recently has been focused on materials with higher stopping power. Higher stopping power can be achieved if the compositions include elements such as Tl (Z=81) or Lu (Z=71), as the compounds gain higher densities and effective atomic numbers. In context of medical imaging this translates into high detection efficiency (count rates), therefore, better image quality (statistics, thinner films) or lower irradiation doses to patients in addition to lowering of cost.
View Article and Find Full Text PDFTwo distinct populations of dark comets delineated by orbits and sizes.
Proc Natl Acad Sci U S A
December 2024
Institute for Astronomy, University of Hawaii, Honolulu, HI 96822.
Small bodies are capable of delivering essential prerequisites for the development of life, such as volatiles and organics, to the terrestrial planets. For example, empirical evidence suggests that water was delivered to the Earth by hydrated planetesimals from distant regions of the Solar System. Recently, several morphologically inactive near-Earth objects were reported to experience significant nongravitational accelerations inconsistent with radiation-based effects, and possibly explained by volatile-driven outgassing.
View Article and Find Full Text PDFFilgotinib in Active Noninfectious Uveitis: The HUMBOLDT Randomized Clinical Trial.
JAMA Ophthalmol
September 2024
Legacy Devers Eye Institute, Portland, Oregon.
Article Synopsis
- - Noninfectious uveitis is a major cause of vision loss and there is a need for better treatment options, prompting the investigation of filgotinib, a JAK1 inhibitor, for this condition.
- - The HUMBOLDT trial was a phase 2 study involving 74 participants, aged 18 and older, with active noninfectious uveitis, comparing filgotinib to a placebo over 52 weeks.
- - Results showed that 37.5% of those on filgotinib experienced treatment failure by week 24, significantly lower than the 67.6% for placebo, indicating that filgotinib may be an effective option for treating this illness.
The Dimorphos ejecta plume properties revealed by LICIACube.
Nature
March 2024
Dipartimento di Ingegneria Industriale, Alma Mater Studiorum, Università di Bologna, Forlì, Italy.
The Double Asteroid Redirection Test (DART) had an impact with Dimorphos (a satellite of the asteroid Didymos) on 26 September 2022. Ground-based observations showed that the Didymos system brightened by a factor of 8.3 after the impact because of ejecta, returning to the pre-impact brightness 23.
View Article and Find Full Text PDFPegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
Lancet
October 2023
Retina Consultants of Texas, Houston, TX, USA; Blanton Eye Institute, Houston, TX, USA; Houston Methodist Hospital, Houston, TX, USA. Electronic address:
Background: Geographic atrophy is a leading cause of progressive, irreversible vision loss. The objectives of OAKS and DERBY were to assess the efficacy and safety of pegcetacoplan compared with sham treatment in patients with geographic atrophy.
Methods: OAKS and DERBY were two 24-month, multicentre, randomised, double-masked, sham-controlled, phase 3 studies, in which patients aged 60 years and older with geographic atrophy secondary to age-related macular degeneration were enrolled at 110 clinical sites and 122 clinical sites worldwide, respectively.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!